Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.
The study was published Dec. 10 in the Journal of Clinical Oncology.
"Our analysis shows that optimal therapy for younger and older patients with chronic lymphocytic leukemia is likely to be different, at least when using current treatments," says first author Dr. Jennifer Woyach, assistant professor of hematology at the OSUCCC – James.
"We hope this study will shape future research by highlighting the importance of enrolling older patients on clinical trials and of developing trials that specifically target older patients."
Doctors diagnose about 15,000 new cases of chronic lymphocytic leukemia (CLL) annually in the United States, making it the most common form of leukemia. It remains incurable, and about 4,400 Americans die of the malignancy each year. CLL most often occurs in people older than age 65; the average age at diagnosis is 72. Yet, most
CLL clinical-trial participants are in their early 60s.
"Our findings apply to both routine care of CLL patients 70 years and older and to future CLL trials," says principal investigator Dr. John Byrd, a CLL specialist and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC – James.
"The study suggests that chlorambucil is superior to fludarabine in older patients, and that CD20 antibody therapies such as rituximab are beneficial as front-line therapy for all CLL patients, regardless of age," says Byrd, who is the D. Warren Brown Designated Chair in Leukemia Research.
"These data also show that future treatment trials for older adults with CLL should build on CD20 antibody therapies such as rituximab and ofatumumab, but not on fludarabine or alemtuzumab."
Byrd, Woyach and their colleagues reviewed 663 CLL patients who were enrolled in four sequential CLL clinical trials evaluating front-line therapies. The researchers looked for differences in treatment outcomes between older and younger patients to identify the most effective therapy for older adults.
The four trials, all sponsored by the Cancer and Leukemia Group B (CALGB) clinical cooperative group, compared these treatments: chlorambucil versus fludarabine, fludarabine plus rituximab versus fludarabine, fludarabine with consolidation alemtuzumab, and fludarabine plus rituximab with consolidation alemtuzumab.
Key conclusions include:
Ohio State University Medical Center: http://medicalcenter.osu.edu/Pages/index.aspx
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
If we want to understand whats happening in the brain when people hear voices, we first need to understand what happens during ordinary inner speechHearing voices: whats your experience when reading?
Seals and sea lions may have brought a form of tuberculosis to the Americas, centuries before the Spanish did so
More people with non-fatal conditions are travelling to assisted dying clinics in Switzerland
We’re all born to adore ourselves, but not all of us grow up
Rumours of dubious treatments are spreading on social media in West Africa, while fishy Ebola treatments are being peddled to anxious US citizens
The type of Ebola erupting in West Africa is closely related to one found 2,500 miles away — the distance between Boston and San Francisco. How did the virus spread so far without anyone noticing?
The tendency of Clostridium novyi to kill mammal cells has been used to shrink tumours in dogs and people, so the bacteria could help fight some cancers
The Burns Collection consists of human cadavers from the early 1800s that were anatomically dissected and preserved to teach anatomy and surgery to medical students. For the first time this portion of the collection is on display to the public as a part of traveling exhibit "Mummies of the World: The Exhibition."
Author Adam Rogers says there are lots of myths about what causes hangovers. His new book, Proof: The Science of Booze, explores these and other scientific mysteries of alcohol's effect on the body.
An experimental vaccine being developed by U.S. government scientists to prevent the painful mosquito-borne viral disease chikungunya has shown promise in its first human trials but remains years away from approval for widespread use.